The impact of molecular medicine upon early cardiovascular drug development.
Lunnon
M W
MW
Cardiovascular Clinical Pharmacology, Division of Clinical Pharmacology, Glaxo Wellcome R & D, Greenford, Middlesex. MWL12467@glaxowellcome.co.uk
Braddock
M
M
D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D015316:Genetic Therapy; D006801:Humans; D008967:Molecular Biology; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use
D002317:Cardiovascular Agents; D016376:Oligonucleotides, Antisense